secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0001193125-24-202879
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharmaceuticals prices $130M stock/warrant offering; net proceeds ~$121.7M
--------------------------------------------------------------------------------

- 8,695,652 shares at $11.50/share and pre-funded warrants for 2,608,922 shares at $11.499/warrant.
- Gross proceeds ~$130M; net proceeds ~$121.7M after underwriting discounts and expenses.
- Offering expected to close August 20, 2024; use proceeds for commercialization and vonoprazan clinical development.
- Joint bookrunners: Evercore ISI, Stifel, Guggenheim; co-managers: H.C. Wainwright, Needham, Craig-Hallum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524202879/0001193125-24-202879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524202879/d816262d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-202879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer